$4.11
-0.09-2.14%
Last update: Nov 12, 9:29 AM
Starling Oncology Inc
STLNNASDAQ
Starling Oncology rose 22.4% from $3.43 to $4.20, ahead of the S&P 500's +11.2%. Its worst day was Nov 6 (−46.0%), and its low came Feb 12 at $2.39.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.14 missed the $-0.12 estimate on $136.6M revenue (est. $122.5M).
+28.9%, the year's best day · S&P 500 0.0%
Starling Oncology closed at its lowest level of the year, 30.5% below where the year started.
Story events cover the past 12 months · Times ET
−9.0% · S&P 500 −1.5%
EPS of $-0.06 beat the $-0.09 estimate on $142.0M revenue (est. $140.3M).
+8.4% · S&P 500 −0.6%
EPS of $-0.02 beat the $-0.08 estimate on $147.4M revenue (est. $142.6M).
−1.7% · S&P 500 +0.8%
EPS of $-0.08 missed the $-0.06 estimate on $161.3M revenue (est. $156.9M); FY revenue guidance of $650.0M–$670.0M against the $657.9M consensus.
+28.5% · S&P 500 +0.6%
Starling Oncology closed at its highest level of the year, 105.5% above where the year started.
+3.2% · S&P 500 0.0%
EPS of $-0.13 missed the $-0.05 estimate on $169.8M revenue (est. $168.6M); FY revenue guidance of $650.0M–$660.0M against the $665.0M consensus.
−46.0%, the year's worst day, on 24M shares, the year's heaviest volume · S&P 500 +0.3%
Where it ended: a close of $4.20 on Nov 11, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.03, revenue est. $177.6M).
Nothing in the past 12 months.
All STLN dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for STLN and SPY from Benzinga historical bars. Not investment advice.
